428.11 +2.73 (0.64%)
After hours: 5:14PM EST
|Bid||430.00 x 1000|
|Ask||433.10 x 1000|
|Day's Range||386.83 - 426.36|
|52 Week Range||271.37 - 442.00|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||23.04|
|Earnings Date||May 04, 2020 - May 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||416.67|
STOCKSTOWATCHTODAY BLOG Monday was the worst day for the U.S. stock markets in two years. The S&P 500 index lost 3.4%, erasing its 2020 gains and more. All 11 of its sectors declined, led by energy’s 4.
The company's Rensselaer County workforce has grown from about 250 to more than 2,900 over the past decade. That number is projected to surpass 4,000 within the next five years.
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.
With the spread of the new coronavirus from Wuhan, investors should consider investing in smaller biotech and pharma players Continue reading...
In a note out Thursday evening, Citi Research analyst Mohit Bansal put his money on (VRTX) the up-and-comer that analysts can’t say enough good things about. “VRTX could be the next entry in the $100B market cap club,” Bansal wrote. (VRTX) (ticker: VRTX) tops Bansal’s ranking of large-cap biotech names, a list that includes (AMGN)(AMGN), (REGN)(REGN), (GILD)(GILD), and (BIIB)(BIIB), among others.
It's been a good week for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shareholders, because the company has just...
SVB Leerink analysts have crunched the numbers, and they say that Paul Hudson, the new CEO of the French drug giant Sanofi, is right in his predictions for the company’s monoclonal antibody Dupixent.
New data highlight importance of proactive EYLEA treatment as more than half of untreated patients in PANORAMA developed vision-threatening events over two years
Regeneron profit was better than expected for the fourth quarter. Sales also beat. But shares dipped Friday. The company said it will provide 2020 guidance by the end of the first quarter.
Regeneron (REGN) delivered earnings and revenue surprises of 8.70% and 3.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?